From: Breast Cancer Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Table 8. Adjuvant Systemic Treatment Options for Women With Stages I, II, IIIA, and Operable IIIC Breast Cancer
| Patient Group | Treatment Options |
|---|---|
| Premenopausal, hormone receptor–positive (ER or PR) | No additional therapy |
| Tamoxifen | |
| Tamoxifen plus chemotherapy | |
| Ovarian function suppression plus tamoxifen | |
| Ovarian function suppression plus aromatase inhibitor | |
| Premenopausal, hormone receptor–negative (ER or PR) | No additional therapy |
| Chemotherapy | |
| Postmenopausal, hormone receptor–positive (ER or PR) | No additional therapy |
| Upfront aromatase inhibitor therapy or tamoxifen followed by aromatase inhibitor with or without chemotherapy | |
| Postmenopausal, hormone receptor–negative (ER or PR) | No additional therapy |
| Chemotherapy |
ER = estrogen receptor; PR = progesterone receptor.